IDH1 and cholangiocarcinoma: Dasatinib is a multi-kinase inhibitor currently used for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia [27] Through novel bioinformatics methods, two separate research groups identified dasatinib as a promising drug candidate to target IDH mutated cholangiocarcinoma [28,29].